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Abstract
Nasal chondrocytes (NC) derive from the same multipotent embryological segment that gives rise to the majority of the maxillofacial bone and
have been reported to differentiate into osteoblast-like cells in vitro. In this study, we assessed the capacity of adult human NC, appropriately
primed towards hypertrophic or osteoblastic differentiation, to form bone tissue in vivo. Hypertrophic induction of NC-based micromass pellets
formed mineralized cartilaginous tissues rich in type X collagen, but upon implantation into subcutaneous pockets of nude mice remained avas-
cular and reverted to stable hyaline-cartilage. In the same ectopic environment, NC embedded into ceramic scaffolds and primed with osteo-
genic medium only sporadically formed intramembranous bone tissue. A clonal study could not demonstrate that the low bone formation
efficiency was related to a possibly small proportion of cells competent to become fully functional osteoblasts. We next tested whether the cues
present in an orthotopic environment could induce a more efficient direct osteoblastic transformation of NC. Using a nude rat calvarial defect
model, we demonstrated that (i) NC directly participated in frank bone formation and (ii) the efficiency of survival and bone formation by NC
was significantly higher than that of reference osteogenic cells, namely bone marrow-derived mesenchymal stromal cells. This study provides a
proof-of-principle that NC have the plasticity to convert into bone cells and thereby represent an easily available cell source to be further investi-
gated for craniofacial bone regeneration.
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Introduction
Cells from the adult nasal septum (nasal chondrocytes, NC) derive
from the same multipotent embryological segment that gives rise to
the majority of the bone and cartilage of the head and face (neural
crest/neuroectoderm) [1]. Human septal cartilage has long been con-
sidered the pacemaker for the growth of the face and skull, with
growth potential equivalent to that of the epiphyseal growth cartilage
of long bones [2]. Adult nasal septal tissue is known to directly inter-
face with facial bone tissue development, thereby regulating turbinate
and maxilla bone growth [3]. In vitro studies have demonstrated that
NC retain a certain level of plasticity and can acquire traits of neuro-
nal- and osteoblast-like phenotypes [4, 5]. However, it is unknown if
NC can induce or directly from frank bone tissue in vivo.
There are two archetypal routes for bone formation and repair:
endochondral and intramembranous ossification [6]. The primary
route in bone development and repair is endochondral ossification, in
which a hypertrophic cartilage template is formed and eventually
remodelled into bone tissue. The bones of the head and face form
and repair predominantly through intramembranous ossification.
Since NC reside within cartilage tissue and are in direct contact with
an environment that forms through intramembranous ossification, in
principle they could have the capacity to form bone through either
ossification route.
In this study, we assessed the capacity of adult human nasal sep-
tum-derived chondrocytes, appropriately primed in vitro through
hypertrophic or osteoblastic differentiation, to form bone tissue in
vivo. NC were cultured also at clonal levels under osteoblastic differ-
entiation conditions to determine the extent of heterogeneity of their
in vitro osteogenic potential. Exploiting both subcutaneous and ortho-
topic cranial in vivo environments, we then assessed whether human
NC could be phenotypically converted to osteoblasts and actively par-
ticipate in the formation of frank bone tissue. The relative easy avail-
ability of a craniofacial-derived somatic cell source [7], capable of
active participation in homotopic bone repair without pre-implantation
genetic manipulation, would provide a significant and clinically rele-
vant advancement in the field of craniofacial bone repair.
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Materials and methods
Methods
Cell source and expansion
All cell sources were obtained in accordance with the local ethical com-
mittee (University Hospital Basel) and subsequent to informed consent.
Nasal septal biopsies were harvested using a punch biopsy tool (6 mm
diameter) by first inserting and gently pushing it into the cartilage, tak-
ing care not to perforate the opposite side. A total of 3 biopsies from 3
different donors (aged from 52 to 76 years old; two females and one
male) were obtained in this manner and used for subsequent experi-
ments. Articular cartilage tissues were harvested post-mortem from full-
thickness biopsies of the femoral condyle of 3 patients (aged from 43
to 67 years old; two males and one female). Chondrocytes (both NC
and articular chondrocytes, AC) were isolated by enzymatic digestion
using collagenase II (Worthington, USA) according to an established
protocol [8] and expanded for two passages (corresponding to approxi-
mately 7 population doublings) in DMEM complete medium [CM; con-
taining 10% foetal bovine serum, 100 mM HEPES buffer solution,
1 mM sodium pyruvate, 100 U/ml penicillin, 100 mg/ml streptomycin
and 292 mg/ml L-glutamine (Gibco, Basel, Switzerland)] supplemented
with 5 ng/ml Fibroblast Growth Factor-2 (FGF-2; R&D Systems, Minnea-
polis, USA). Medium was changed twice a week. Upon confluence, cells
were enzymatically retrieved, counted and used as described below.
Human bone marrow-derived mesenchymal stromal cells (BMSC; used
as a control throughout this study) were isolated from marrow aspirates
(volume ~20 ml) obtained from the iliac crest [9] of three patients (37–
45 years old, 2 males and 1 female) and expanded for two passages
(corresponding to approximately 14 cell population doublings) in a-
Modified Eagle’s Medium (aMEM) based CM in the presence of 5 ng/ml
FGF-2 to enhance their post-expansion bone forming capacity [10].
Cell-based construct fabrication and culture
Constructs recapitulating the endochondral ossification route were
established using a previously described pellet culture system [11].
Briefly, cells (500,000) were centrifuged in 1.5 ml conical polypropylene
tubes (Sarstedt, Numbrecht, Germany) to form spherical pellets. Pellets
were then cultured in serum free medium (SFM) consisting of DMEM,
4.5 mg/ml D-Glucose, 0.1 mM nonessential amino acids, 1 mM sodium
pyruvate, 100 mM HEPES buffer, 100 U/ml penicillin, 100 mg/ml strep-
tomycin, 0.29 mg/ml L-glutamine and Insulin-Transferrin-Selenium
(ITS+1) supplemented with 0.1 mM ascorbic acid 2-phosphate, 10 ng/
ml transforming growth factor-b1 (TGF-b1) and 108 M dexamethasone
[12]. After 3 weeks of chondrogenic culture, medium was changed to
hypertrophic induction medium, which consisted of SFM supplemented
with 0.1 mM L-ascorbic acid 2-phosphate, 108 M dexamethasone,
50 nM thyroxine and 10 mM b-glycerophosphate [13]. For each experi-
ment and experimental group, at least 2–3 replicate pellets were
assessed for each analysis.
Constructs recapitulating intramembranous ossification were estab-
lished by loading 1 million expanded cells after one passage (average of
4.5 doublings) onto porous calcium phosphate granules (ActifuseTMMi-
crogranules, Apatech, Foxborough, MA, USA) using fibrin gel as a cell
carrier, as previously described [14]. To obtain the fibrin mesh, fibrino-
gen and thrombin components from Tisseel VH S/D (Baxter BioScience,
Vienna, Austria) were diluted and mixed as described previously [15].
The fibrinogen component (containing 75–115 mg/ml fibrinogen, +3000
KIE/ml aprotinin) and the thrombin component (containing 400–600 IU/l
thrombin + 40 mmol/l calcium chloride) were diluted three and fourfold,
respectively, using the specific buffers provided by Baxter. All constructs
were maintained in osteogenic medium for 2 weeks before being either
ectopically or orthotopically implanted. Osteogenic medium consisted of
aMEM CM supplemented with 108 M dexamethasone, 0.1 mM L-ascor-
bic acid-2-phosphate and 10 mM b-glycerolphosphate. The above experi-
mental procedure was applied for both NC and BMSC and for both cell
types under equivalent conditions.
Clonal production
Nasal chondrocytes were isolated and clonal populations generated
according to a previously established procedure [16]. Briefly, cells were
extracted from the native nasal septum tissue biopsy (whole popula-
tion). Single cells from this whole population were plated into one well
of a 96-well plate and expanded in DMEM CM supplemented with 1 ng/
ml TGF-b1 and 5 ng/ml FGF-2 [17]. Colonies deriving from a single cell
were expanded for 3 passages (corresponding to approximately 22 dou-
blings) (clonal population) before testing their osteoblastic differentia-
tion capacity in established in vitro assays. Individual colonies were
also tested in vivo for 8 weeks in subcutaneous pouches using the in-
tramembranous ossification constructs described above.
Animal models
All in vivo procedures were performed in accordance with the standards
and protocols of both the University Hospital Basel, Switzerland and
Radboud University Nijmegen Medical Centre, Nijmegen, the Nether-
lands. National guidelines for care and use of laboratory animals were
followed and approval was obtained from the country’s governing body
in which the experimentation occurred.
For subcutaneous implantations, constructs were implanted into the
subcutaneous tissue of nude mice (CD1 nu/nu, athymic, 6–8 week-old
females, Charles River, Sulzfeld, Germany). Constructs from the same
experimental group were implanted in different mice, with up to four con-
structs implanted per mouse. A total of 6 replicates per experimental
group resulted in the use of 5 mice. For orthotopic implantations, bilateral
calvarial defects were made in 4 week-old, male nude rats (Crl:NIH-
Foxn1rnu, Charles River) as previously described [18]. Constructs were
placed into the defects and molded to increase as much as possible the
bone to construct contact. Finally, the periosteum and the scalp were
closed with 3.0 and 4.0 Vicryl resorbable sutures (Johnson & Johnson,
St. Stevens-Woluwe, Belgium). For both subcutaneous and orthotopic
implantations, constructs remained in vivo for a total of 12 weeks, where-
upon the mice or rats were killed by inhalation of CO2. The constructs
were harvested, fixed in 1.5% paraformaldehyde overnight and processed
as described below. Redundant. Already described in first paragraph.
Analytical methods
Histology
Explanted constructs were fixed overnight in 1.5% paraformaldehyde at
4°C. Ceramic-based constructs were then subjected to slow decalcifica-
tion in 7% w/v EDTA and 10% w/v sucrose (both from Sigma-Aldrich,
Saint Louis, USA) at 37°C on an orbital shaker for 7–10 days. Decalcifi-
cation solution was refreshed daily. All constructs were then paraffin
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embedded (TPC15 Medite, Burgdorf, Germany), sectioned (6-lm-thick)
by means of a microtome (Leica, Wetzlar, Germany) and processed for
histological, histochemical and immunohistochemical stainings as fol-
lows. Standard haematoxylin and eosin (Baker) staining was performed
to identify bone tissue formation and maturation stage. According to
conventional definitions and in contrast to mere condensation of collag-
enous structures, frank bone tissue was identified as uniform eosin-pink
stained regions, often including a visible rim of lining osteoblasts.
Based on haematoxylin and eosin stained sections, quantification of
total de novo bone area was performed based on 3 different depth sec-
tions of 3 different explants (n = 9). Total bone area was calculated
automatically by totaling the sum of all traced contours of de novo bone
spots using CellSense Dimension software (Olympus, Tokyo, Japan).
Safranin-O (Fluka, Buchs, Switzerland) staining allowed investigating the
presence of sulphated proteoglycans inside the construct, characteristic
of cartilaginous tissue. The matrix characterization in cartilaginous con-
structs was assessed by immunostaining for human collagen type II
(COLL II) and collagen type X (COLL X) (MP Biomedicals LLC, Santa
Ana, USA and Abcam PLC, Cambridge, UK respectively). Upon
rehydratation in ethanol series, sections were treated as described pre-
viously for antigen retrieval for COLL X according to the manufacturer’s
instructions [13]. The presence of vessels was detected by immuno-
staining for CD31 (Abcam 28364). The immunobinding was detected
with biotinylated secondary antibodies and using the appropriate Vecta-
stain ABC kits (Vector Laboratories, Burlingame, USA). The red signal
was developed with the Fast Red kit (Dako Cytomation Dako, Glostrup,
Denmark) and sections counterstained by Haematoxylin. Negative con-
trols were performed during each analysis by omitting the primary anti-
bodies. Human cells in the explants were identified by chromogenic in
situ hybridisation for the human-specific sequence ALU, using a biotin-
conjugated DNA probe (ZytoVision GMBH, Bremerhaven, Germany), as
per the manufacturers guidelines. Histological and immunohistochemical
sections were analysed using an Olympus BX-61 microscope.
Calcium and DNA quantification
Extracellular matrix associated calcium present on all applicable con-
structs was determined colorimetrically on a Spectra Max 190 micro-
plate colorimeter (Molecular Devices, Sunnyvale, USA) as previously
described [19] and as per the manufacturer’s protocol (Total Calcium
Assay, Randox, Crumlin, UK). Total calcium was normalized to total
DNA present in a replicate construct.
To quantify total DNA per construct, collected samples were digested
with proteinase K solution (1 mg/ml proteinase K, 50 mM TRIS, 1 mM
EDTA, 1 mM iodoacetamide, and 10 mg/ml pepstatin-A (Sigma-Aldrich)
in double distilled water or potassium phosphate buffer for 16 hrs at
56°C as previously described [20]. DNA quantification was performed
by means of CyQUANT Cell Proliferation Assay (Invitrogen, Waltham,
USA). Working solutions were prepared according to the manufacturer’s
protocols. The analyses were carried out measuring fluorescence with a
Spectra Max Gemini XS Microplate Spectrofluorometer (Molecular
Devices). Excitation and emission wavelengths were, respectively, 485
and 538 nm. Samples in each plate included a calibration curve. Each
sample was measured in triplicate.
Real-time PCR
Total RNA extraction, cDNA synthesis and real-time reverse transcrip-
tase-polymerase chain reaction (RT-PCR; 7300 AB Applied Biosystems,
Foster City, USA) were performed to quantify expression levels of the
following genes of interest: COLL II, COLL X, bone sialoprotein (BSP),
osteocalcin (OC) [16], collagen type I (COLL I), osteopontin (OP),
osteonectin (ON), RUNX2, bone morphogenetic protein 2 (BMP2), bone
morphogenic protein 4 (BMP4-Applied Biosystems Ref. number:
Hs00181626_m1), Matrix Metalloproteinase-13 (MMP13-Applied Biosys-
tems, Ref. number: Hs00233992_m1), alkaline phosphatase (ALP-
Applied Biosystems Ref. number: Hs01029144_m1), osterix (SP7-
Applied Biosystems, Ref. number: Hs00541729_m1), indian hedgehog
homolog (IHH-Applied Biosystems, Ref. number: Hs01081800_m1), gli-
oma associated oncogene homolog-1 (GLI1-Applied Biosystems, Ref.
number: Hs00171790_m1), parathyroid hormone 1 receptor (PTH1R-
Applied Biosystems, Ref. number: Hs00174895_m1), bone morphoge-
netic protein 4 (BMP-4, Applied Biosystems, Ref. number:
Hs00181626_m1), and chondromodulin (LECT1, Applied Biosystems,
Ref. number: Hs00993254_m1). Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) was used as housekeeping, reference gene.
Statistics
Data are presented as mean  SD; N is indicated in the figure legends.
For statistical testing one-way ANOVA was performed for multi-condition
experiments using the Graphpad Prism software (Version 5.02, Graph-
pad Software, San Diego, USA).
Results
In vitro hypertrophic NC form stable cartilage
in vivo
We first tested endochondral ossification as a potential bone forming
route for NC. Using a previously established protocol for the produc-
tion of engineered hypertrophic cartilage tissues using BMSC [13],
expanded NC were cultured as pellets in chondrogenic medium fol-
lowed by hypertrophic induction. After chondrogenic induction, the
resulting tissues displayed clear cartilaginous features, including
positive Safranin-O staining for glycosaminoglycans (GAG) (Fig. 1A)
and large cells in lacunae embedded in abundant, mineral free matrix
positive for COLL II (data not shown). Subsequent hypertrophic
induction produced areas of enlarged cells (Fig. 1B) with associated
mineral deposition (Fig. 1C) and positively stained for COLL X
(Fig. 1D). The expression of genes encoding for the above proteins
matched the immunohistochemical findings and paralleled the
expression profiles found in BMSC undergoing the same culture
regime, including up-regulation of BSP and COLL-10 (Fig. 1E). Analy-
sis of the pathways involved in endochondral ossification on cells
from the hypertrophy-induced constructs showed up-regulation of
IHH, PTH1R and GLI1 to levels approaching those reached by BMSC
and clearly distinct from AC (Fig. 1E).
Implantation into subcutaneous pockets of nude mice of both
chondrogenic- and hypertrophy-induced constructs (n = 3) yielded
similar results at the analysed time-points. Hypertrophic explants
underwent remodelling in vivo, resulting after 5 weeks in a marked
decrease in Safranin-O staining intensity and of positivity for COLL
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X immunostaining (Fig. 1F). After 12 weeks in vivo, NC-based con-
structs consistently established a GAG-rich cartilage tissue
(Fig. 1G) negative for COLL X (data not shown), in contrast to
BMSC-based constructs which proceeded throughout endochondral
ossification as previously described (Fig. 1I) [13]. Successful
endochondral bone remodelling is known to hinge upon the vascu-
larization of the implanted construct [21], whereas CD31 staining
of explanted NC-based constructs demonstrated a total lack of
vessel invasion from the host vasculature (Fig. 1H). Additionally,
the mRNA expression of chondromodulin, a potent anti-angiogenic
A
E
B C D
F
J
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Fig. 1 NC can form hypertrophic-like tissue in vitro, but revert to stable cartilage in
vivo. In vitro analysis: Safranin-O staining of (A) chondrogenic- and (B) hypertro-
phic-induced NC constructs with (C) corresponding alizarin red staining of hyper-
trophic-induced NC constructs. (D) Immunohistochemistry staining of collagen
type X in hypertrophic-induced NC constructs. (E) Gene expression analysis of NC
(bars) compared to hypertrophic-induced AC (black dotted lines) and BMSC (black
solid lines); n = 3. In vivo analysis: (F) Safranin-O and Collagen type X (upper left
insert) staining of NC-based in vitro hypertrophic-induced constructs explanted
after 5 weeks. (G) Safranin-O staining of NC-based in vitro hypertrophic-induced
constructs explanted after 12 weeks subcutaneous implantation. (H) Immunohisto-
chemistry staining of CD31 in 12 week explants. (I) Masson’s trichrome staining of
BMSC-based in vitro hypertrophic-induced constructs explanted after 12 weeks
subcutaneous implantation. (J) Real-time RT-PCR analyses carried out using spe-
cific primers for chondromodulin expressed by expanded NC and NC cultured under
chondrogenic or hyperthrophic conditions. Levels are normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Values are mean  SD of
n = 3 donors performed in duplicates, ***P ≤ 0.001. nd = under the limit of detection. Scale bars = 100 lm; nd = under the limit of detection. scale
bars are the same for A–D and F–I. For all immunohistochemical analyses negative controls omitting the primary antibodies were performed resulting in
the absence of the specific signals (data not shown).
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factor specific to cartilage [22], was strongly up-regulated in NC
during chondrogenic differentiation and hypertrophic induction.
This was in contrast to BMSC, which maintained a statistically sig-
nificant lower expression level throughout hypertrophy (Fig. 1J). In
summary, we demonstrated that NC can acquire a phenotype char-
acteristic of hypertrophic cartilage under in vitro stimulation, but
then revert back to stable chondrocytes upon in vivo implantation
in a subcutaneous environment.
Intramembranous ossification of NC in a
subcutaneous environment is inefficient
We next analysed the capacity of NC to differentiate directly
towards an osteoblastic phenotype in vitro and then undergo
intramembranous ossification upon implantation in vivo. Expanded
NC were exposed to osteogenic stimuli in either monolayer cul-
tures (2D) or after embedding within ceramic-fibrin materials
(3D). In 2D cultures, accumulation of mineral deposits in the
extracellular matrix reached levels similar to those of BMSC
(Fig. 2A). Quantification of calcium per cell deposited onto the
matrix was consistent with the intensity of alizarin red staining
and indicated that osteogenically cultured NC could mineralize the
ECM to an intermediate level between AC and BMSC (Fig. 2B).
Osteogenic stimulation in 2D culture resulted in the up-regulation
of osteoblast-related genes, e.g. RUNX2 and ALP. Up-regulation
of further osteoblastic genes, e.g. BMP2, OP and COLL-1,
occurred in the 3D culture system, although BSP and osterix lev-
els remained undetectable, indicating that in vitro osteogenically
differentiated NC did not become fully functional osteoblastic
A
C
D
B
Fig. 2 NC can osteoblastically differentiate,
but do not efficiently proceed through in-
tramembranous ossification in a subcuta-
neous environment. (A) Alizarin red
staining of NC following osteogenic cul-
ture conditions (upper right box = BMSC
under same conditions; lower right
box = low magnification of whole well NC;
scale bar = 1 mm). (B) Quantification of
calcium matrix deposition of NC in com-
plete medium (CM) and osteogenic med-
ium (OM). Solid and dotted black lines
represent calcium values for BMSC and
AC, respectively, when cultured in OM.
*P < 0.05; n = 3. (C) Gene expression
levels of NC after expansion, after
2 weeks osteogenic induction in a mono-
layer (2D-T14) and after 2 weeks
osteogenic induction in a 3D construct
(3D-T14). Dotted line represents BMSC
expression values at 3D-T14 time-point.
nd = under the limit of detection.
***P < 0.001; represented significant dif-
ferences noted only for selected markers
of osteoblastic differentiation comparing
2D-T0 to 3D-T14; n = 3. (D) Haematoxylin
and eosin staining of NC (left; one of only
two bone ossicles detected) and BMSC
(right) explanted 3D constructs after
8 weeks in vivo. Inserts are low magnifi-
cation images of the entire constructs;
scale bar = 100 lm.
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cells. There was also an up-regulation of PTH1R and IHH in 3D
constructs (8 and 10 times, respectively), but expression levels
remained over 4 orders of magnitude lower than those seen dur-
ing hypertrophic induction (Fig. 2C), suggesting minimal hedge-
hog pathway activity. Implantation of 3D constructs (n = 3) after
osteogenic differentiation into subcutaneous pockets of nude mice
resulted in limited bone formation (only 2 scattered small bone
regions) in only 1 of the 3 donors tested, while BMSC resulted
in robust bone formation (reproducible presence of several frank
bone areas in each construct; Fig. 2D). We then decided to test
whether this inefficient production of bone was a result of a lim-
ited fraction of cells present in the whole NC population that
would be capable of osteogenic differentiation and bone matrix
deposition.
Clonal strains of NC have heterogeneous
osteoblastic differentiation capacities
A clonal study was performed to investigate the percentage of cells
with osteogenic capacity present within the whole extracted NC popu-
lation. The colony forming efficiency of NC, here defined as the per-
centage of plated single cells able to form a colony, was 36.5%.
During the extensive expansion phase, including two passages, NC
clones maintained an average proliferation rate of 0.90  0.16 dou-
blings/day, resulting in an average of 22.6  1.1 total doublings.
Cells isolated from the individual colonies were cultured in 2D in oste-
ogenic medium. Mineralization capacity of the individual NC clonal
populations was highly heterogeneous, as assessed by alizarin red
staining and quantification of the amount of deposited calcium
(Fig. 3A). Expression analysis of the master gene for osteoblastic dif-
ferentiation (RUNX2) [23–25] showed a positive correlation between
its up-regulation and the mineralization capacity of the clonal strains
(Fig. 3B). Upon combination with fibrin-ceramic granules and implan-
tation into subcutaneous pouches of nude mice, variances in matrix
density were observed between implanted clones. In particular, clonal
populations expressing higher amounts of RUNX2 in vitro resulted in
higher tissue densities in vivo (Fig. 3C). However, no individual clone
was able to generate frank bone tissue.
NC participate in bone formation in an orthotopic
environment
We next hypothesized that an orthotopic environment could be neces-
sary to support the NC towards more efficient bone formation. We
thus implanted osteogenically induced NC and BMSC (n = 3) in 3D con-
structs into bilateral calvarial defects for 8 weeks. Upon explantation,
A B
C
Fig. 3 Clonal populations representing elevated intradonor heterogeneity and osteogenic capacity within a whole NC population. (A) Alizarin red stain-
ing of matrix obtained after 2 weeks osteogenic induction of all the individual clones from total population of NC. Numbers in bottom left of each
image refer to total calcium (lg Ca/lg DNA) associated with a duplicate well. Lower right black-boxed image represents whole NC population. (B)
qPCR of RUNX2 expression in NC clonal populations following osteogenic stimulation; n = 4. (C) Representative haematoxylin and eosin (upper
row) and red filter florescence imaging of haematoxylin and eosin stained tissues to show relative collagen fibril densities (lower row) of explanted
clones; Left column = NC high; right column = NC low. NC high = clones with intense alizarin red staining (indicated with white asterisk); NC
low = clones with little to no alizarin red staining (indicated with black asterisk). S = decalcified scaffold (no cells present), P = pores of the scaf-
fold (presence of cells and tissue development); scale bars = 100 lm.
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two types of bone formation were observed: ingrowth bone from sur-
gical margins, indicative of osteoconduction, and detached bone, here
defined as ossicles without osseous link to the ingrowth bone, indica-
tive of osteogenesis (Fig. 4A and B). Human cells were found
throughout the repair tissue, as assessed by Alu sequence staining,
and also within the areas of detached bone (Fig. 4C and Fig. S1).
Quantification of detached bone volume areas in explanted constructs
revealed an average of over 5 times more bone formation by NC than
by BMSC (Fig. 4D). Micro-CT analysis indicated that, while bone was
found to be present even in the centre of the constructs, total
detached bone volume decreased with the distance from the defect
edges (Fig. 4E). This finding suggests that the construct itself was
A
C D
E
B
Fig. 4 NC participate in bone formation in
calvarian bone defects. Haematoxylin and
eosin staining of explanted NC-based (A)
and BMSC-based (B) constructs; Bottom
images for both A and B are red filter flo-
rescence imaging of haematoxylin and
eosin stained tissues to show relative col-
lagen fibril densities; scale bar = 1 mm.
Black and white arrows in A indicate
detached bone ossicles. (C) In situ hybrid-
ization of human specific Alu sequences
in an NC-based explanted construct; black
arrows point to human nuclei; scale
bar = 100 lm. (D) Histological section-
based quantification of total detached
bone volume; n = 3. (E) MicroCT-based
quantification of detached bone formation
(osteogenesis) 8 weeks after implantation
into calvarial defects, demonstrating
decreasing bone formation towards the
centre of the construct. MicroCT was per-
formed as described by Scotti et al. [13].
Values are means  SD of n = 9 per
group (for each of the 3 implants per
group, 3 regions were quantified). Signifi-
cant differences from one experimental
group to both other groups is indicated;
**P < 0.01. ROI = region of interest.
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not intrinsically osteoinductive, but the soluble signals from the native
bone defect were responsible for the osteoblastic switch of the NC
(Fig. 4E). The result could be alternatively explained by an increased
mortality of NC in the inner implant regions, as a result of lack of
nutrients at the time of implantation. Interestingly, no BMSC were
detected in the explants, whereas NC remained viable and were pres-
ent throughout the de novo-formed tissue within the explants
(Fig. S1).
Discussion
This study provides a proof-of-principle that NC can directly convert
into bone cells and actively participate in bone tissue formation. This
was not observed in ectopic implantation models, even following
hypertrophic or osteoblastic in vitro priming or clonal selection, but
critically required a craniofacial, orthotopic in vivo environment. In
that model, the efficiency of survival and bone formation by NC was
significantly higher than that of reference osteogenic cells, namely
BMSC.
Considering NC normally form a cartilage tissue in situ, we first
wanted to determine if they could proceed through endochondral
ossification. The phenotype acquired by NC after in vitro hypertro-
phic induction resembled that of BMSC, not only including COLL X
deposition, but also the acquisition of a genetic signature known to
be reflective of endochondral ossification [13]. While BMSC could
effectively form a functional bone organ in vivo after in vitro stimu-
lation to a hypertrophic phenotype [26], under the same conditions
NC did not develop into bone, but rather formed a stable cartilage
tissue. The inability of NC to continue through the endochondral
ossification route suggests that typical markers associated with
endochondral bone formation (e.g., COLL X and IHH) [27] are not
sufficient to establish the process. Considering that vascularization
is critically required for endochondral bone formation in vivo [21],
our finding could be related with the elevated production by NC of
chondromodulin, a strong anti-angiogenic factor implicated in block-
ing hypertrophic cartilage vascularization and subsequent tissue
turnover to bone [28].
Direct in vitro osteogenic stimulation of NC demonstrated that
not only could NC produce a mineralized extracellular matrix just as
effectively as BMSC, but that NC acquired a genetic profile similar to
BMSC under the same conditions. In 3D culture, NC up-regulation of
BMP2 and OP, combined with downregulation of the chondrogenic
factor BMP4, is consistent with the osteoblastic differentiation pro-
files previously reported in neural crest progenitors [29]. IHH was
not up-regulated during osteogenic differentiation, consistent with
the findings that its expression by neuroectodermally derived pre-os-
teoblasts inhibits further osteoblastic differentiation [30]. In a subcu-
taneous implant environment, NC were capable to form frank bone
tissue at a very low efficiency, suggesting that either the in vitro
pre-osteogenic commitment was not stable enough to have a rele-
vant in vivo effect or that only a small proportion of cells were com-
petent to become fully functional osteoblasts. A clonal study
designed to address the latter hypothesis demonstrated that none of
the clonal strains implanted ectopically resulted in bone formation.
However, these findings could have been intrinsically biased by the
extensive population doublings underwent by the clonal populations
(average of 22) as compared to the typical ones (average of 4.5)
required for expansion of a whole NC population. Extensive prolifera-
tion has in fact been associated with the loss of in vivo osteogenic
differentiation capacity in other mesenchymal precursor cell systems
[31, 32]. Although the clonal experiments designed to explain the
limited efficiency were not conclusive, the results of the multiclonal
implantation proved that NC have the capacity to form frank bone
tissue by direct osteoblastic differentiation, in contrast to the previ-
ously targeted route of endochondral ossification. Indeed, Calloni
et al. postulated that bone cells from the craniofacial region arise
from specific progenitors distinct from the osteochondrogenic,
endochondral like ones found in long bones [25], thus further sup-
porting a preferential capacity of NC to undergo intramembranous
ossification.
To induce a more efficient direct osteoblastic transformation of
NC, we next tested the cues present in an orthotopic environment.
The cranial defect model used in this study reflects not only a bone
environment that forms and heals through intramembranous ossifi-
cation [33–35], but also a mixed embryological origin site providing
homotopic (neuroectodermally- and mesodermally derived) signals
for both cell types implanted (NC and BMSC) [36–38]. Using this
model we demonstrated, for the first time to the best of our knowl-
edge, that a population with a previously considered stable chondr-
ocytic phenotype could be converted into osteoblastic cells forming
frank bone tissue in vivo. The behaviour of NC is different from that
of AC, reported to form stable cartilage when implanted into calvari-
al defects [39], and could be reminiscent of embryonic neural
crest-derived cells, which supported bone healing in a cranial defect
upon differentiation into chondrocytes [40, 41]. Unexpectedly, under
our experimental conditions, NC-based constructs outperformed
BMSC-based ones in terms of osteogenesis and survival in the
repair tissue. Indeed while large numbers of human NC could be
detected in the repair tissue, no living BMSC could be observed.
Obviously we cannot exclude that very few BMSC did survive, in
which case their contribution to bone formation would likely be
appreciated only after longer in vivo time. Mankani et al. in fact
reported that bone formation by human BMSC in the calvarial
defects of rats occurred at time-points superior to 8 week [42]. Col-
lectively, these results indicate that the implanted BMSC have a
positive influence on vascularization and osteogenesis primarily by
the release of trophic factors [43–45] as opposed to the survival
after acquisition of an osteoblastic phenotype. Instead, the direct
contribution of NC to bone formation, at least in the assessed time
frame, demonstrates an intrinsically different mode of action, possi-
bly related to the homotopic neuroectoderm nature of the cell origin
and implantation site [46, 47]. Further studies will be necessary to
investigate which environmental cues are responsible for the osteo-
genic induction of NC at the orthotopic and homotopic site, as well
as to further characterize whether or not only specific subpopula-
tions of NC can be effectively converted into osteoblasts. Indeed, it
cannot be excluded that bone tissue was formed in our model by
undifferentiated mesenchymal progenitors, either included within
the nasal cartilage or – despite meticulous separation from the
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perichondral membrane – derived from a contaminant population
from surrounding tissues.
A cell-based therapy has the potential to accelerate and improve
the repair efficiency of critically sized craniofacial defects, but an ade-
quate cell source has yet to be identified [48]. Common cell-based
strategies rely on BMSC or apical bone-derived osteoblasts, both of
which display limited repair capacities [49] and associated drawbacks
(low yield, donor site morbidity and high intradonor variability). NC
could represent a homotopic cell source accessible under minimally
invasive conditions and possibly used in autologous settings. Autolo-
gous NC have recently been clinically used for the reconstruction of
the alar lobule [50] and are currently being tested for the treatment of
articular cartilage defects at the University Hospital Basel (clinicaltri-
als.gov identifier: NCT01605201) [51]. Their demonstrated ability to
directly convert into a functional bone cell provides a proof-of-princi-
ple that the same cells may be further investigated in pre-clinical
models for bone regeneration.
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